Detailed Narrative
Global Economic Scenario and Outlook
The global economy is experiencing moderate growth amid persistent challenges such as high debt levels, weak investment, and ongoing geopolitical tensions, including trade disputes involving major economies like the U.S., China, and the European Union. Despite these uncertainties, management maintains a positive outlook for FY26, anticipating mid-double-digit revenue growth. They acknowledge potential impacts from US tariffs but also see opportunities for business shifts.
Q4 and Full Year FY25 Financial Performance
For Q4 FY25, Advanced Enzyme reported a revenue of INR 1,672 million, marking a 6% YoY growth but a 1% sequential degrowth. EBITDA stood at INR 456 million, with a margin of 27%, down from 31% in the previous quarter and Q4 FY24, primarily due to product mix changes and year-end inventory valuation true-ups. Full-year FY25 revenue grew 2% to INR 6,369 million, with EBITDA at INR 1,944 million (31% of sales) and PAT at INR 1,340 million (21% of sales).
Segmental Performance and Key Product Trends
In Q4 FY25, Human Nutrition contributed 62% of revenue, growing 1% YoY. Animal Nutrition grew 13% YoY, contributing 12%. Bio-Processing contributed 17% with 8% YoY growth, while Specialized Manufacturing showed strong 39% YoY growth, contributing 9%. For FY25, Human Nutrition revenue declined by approximately 3% (INR 132 million), mainly from domestic markets. Serratiopeptidase, a key product, saw its revenue decline to INR 1,193 million in FY25 from INR 1,310 million in FY24, with management expecting a further 2-5% fall in FY26 due to competitive pressures.
R&D and Innovation Initiatives
Advanced Enzyme increased its consolidated R&D expenditure to 5.3% of revenue in FY25, up from 4.53% in FY24, reflecting a commitment to long-term growth. The company filed a food enzyme dossier for approval in Europe and two GRAS Dossiers with the U.S. FDA for food processing enzymes. Additionally, three patent applications related to innovative sugar management technologies were filed. The construction of a new 5-floor R&D center is on track for completion by December 2025, with some AI implementation expected this year.
Sustainability and Subsidiary Performance
The company enhanced its sustainability efforts by installing an additional 350-kilowatt solar power plant, bringing its total clean energy capacity to 510 kilowatts. This plant generated 315,000 units last year, covering 5-10% of the Sinnar facility's consumption. Subsidiary performance was mixed: JC Biotech's revenue was INR 600 million with PAT of INR 12 million in FY25. Evoxx reported a loss of INR 39 million in FY25, though management expects a turnaround in FY26. SciTech demonstrated strong growth, with revenue of INR 542 million (+30% YoY) and PAT of INR 37 million in FY25.
Strategic Focus and Future Growth Drivers
Management is optimistic about FY26, projecting mid-double-digit revenue growth. Key growth drivers are expected to be the biocatalyst area and animal feed business, with Specialized Manufacturing also anticipated to grow over 20%. The company aims to maintain gross contribution margins at 76-77% and EBITDA margins at around 31%. Efforts are underway to expand marketing reach in overseas markets and improve product registration processes, particularly for the animal feed segment.